Ischemic cardiovascular and cerebrovascular diseases (ICCDs), including thrombosis,
ischemic stroke and atherosclerosis, represent a significant threat to human health, and …

Acute lung injury (ALI) is a common complication in patients with severe burns and has a
complex pathogenesis and high morbidity and mortality rates. A variety of drugs have been …

Thrombotic cardiovascular diseases are a prevalent factor contributing to both physical
impairment and mortality. Thrombolysis and ischemic mitigation have emerged as leading …

The prospective of percutaneous drug delivery (PDD) mechanisms to address the limitations
of oral and injectable treatment for rheumatoid arthritis (RA) is increasing. These limitations …

The management of diabetic kidney disease (DKD) faces challenges stemming from
intricate pathologies and suboptimal biodistributions during drug delivery. Although clinically …

Thrombosis is the major cause of cardiovascular diseases. Only a small subset of patients
could benefit from thrombolytic therapy due to the high bleeding risk brought about by the …

Thrombosis presents a critical health threat globally, with high mortality and incidence rates.
Clinical treatment faces challenges such as low thrombolytic agent bioavailability …

Thrombus-induced cardiovascular diseases threaten human health. Current treatment
strategies often rely on urokinase plasminogen activator (uPA) for its efficacy, yet it has such …

A new approach to treating vascular blockages has been developed to overcome the
limitations of current thrombolytic therapies. This approach involves biosafety and …

The rapid progress in the fields of biomedical and biological photonic sciences has given
rise to a substantial demand for biological photonic structures capable of interacting with …